📌 Is ABBV a Buy right now?
According to Ultra Stock Analysis Pro, AbbVie Inc. (ABBV) is currently rated WAIT (Signal Strength: 0/7). The long-term fundamentals are strong (P/E: 103.1, Revenue Growth: +12.4%), while short-term technicals show a bearish trend (RSI: 55). Consider waiting for support confirmation near $213.00 before adding exposure.
For the latest stock analysis and interactive charts:
📊 Open ABBV Analysis ↗
Why this rating?
The Ultra Stock Analysis algorithm has assigned a WAIT rating to ABBV based on a confluence of 3 distinct factors:
📊 Confidence Interval:
Based on 7+ years of historical data, signals with this specific technical fingerprint have resulted in a positive return 67% of the time over a medium-term (months) hold period, with an average return of +9.2% per trade.
To assist with risk management, here are the three most probable paths for ABBV over the next trading week:
🟢 The Bull Case (Probability: 20%)
If ABBV reclaims the $213.00 resistance level (Bollinger Upper), algorithmic targets shift to $252.93. This move would likely be driven by continued sector rotation into Healthcare.
🔴 The Bear Case (Probability: 50%)
Failure to hold the $195.98 support zone (Bollinger Lower) triggers a defensive stop-loss signal. In this scenario, the algorithm projects a slide toward the $190.53 liquidity zone (-9.4% from current price).
🟡 The Base Case (Sideways)
Given the current ADX of 17 (weak trend - consolidation likely), the most likely immediate outcome is consolidation between $195.98 and $213.00 until a volume catalyst occurs.
⚠️ These scenarios are algorithm-generated projections based on technical analysis, not financial advice. Past performance does not guarantee future results.
| TECHNICAL METRICS | VALUE | FUNDAMENTAL METRICS | VALUE |
|---|---|---|---|
| Current Price | $210.39 | Market Cap | $371.7B |
| Past Win Rate (Backtest) | 66.7% | Forward P/E | 13.0x |
| Past Total Return | +39.6% | Analyst Target | $252.93 |
| RSI / Trend Strength | 55 / 17 | Upside to Target | +20.2% |
| MACD Signal | Bearish | Revenue Growth | +12.4% |
| Profit Factor | 2.43 | Institutional Own. | 76.9% |
| Position Entry | 2026-04-29 @ $203.89 | Analyst Ratings | 21 Buy / 9 Hold / 1 Sell |
| Open Position Past P&L | +3.2% |
MAINTAIN POSITION - Current position showing 3.2% unrealized gain. Use intelligent stop loss strategy below.
Both strategies analyzed independently. Conservative uses fixed 2.0x ATR stops. Hybrid adapts stops based on position profit (tighter as profit grows).
Fixed 2.0x ATR Stop Loss
Entry: $203.89 on 2026-04-29
Confluence: 5.0
Stop Loss: $199.50
Backtest Results (Since 2018):
Past Win Rate
67%
Past Total Return
+39.6%
Max Drawdown
-15.9%
Avg Trade
+9.2%
Trades
15
Adaptive ATR Stop Loss (1.0-2.75x)
Entry: $203.89 on 2026-04-29
Confluence: 5.0
Stop Loss: $202.22
Backtest Results (Since 2018):
Past Win Rate
58%
Past Total Return
+52.7%
Max Drawdown
-15.8%
Avg Trade
+5.6%
Trades
24
Current Price
$210.39
Buy Stop Loss
$199.50
Distance: 5%
Conservative 2.0x
Position Stop Loss
$199.50
Distance: 5%
Hybrid 2.00x
ATR 14 Day
$5.44
Volatility
ADX Strength
16.9
Weak/No Trend
Position up +3% - Adaptive strategy adjusts for momentum
ADX: 20-25 = Emerging trend | 25-50 = Strong trend | 50+ = Very strong
| Indicator | Value | Signal |
|---|---|---|
| EMA 20 | $206.57 | Bullish |
| EMA 50 | $209.97 | Bullish |
| RSI (14) | 55.3 | Neutral range |
| Trend Strength (ADX) | 16.9 | Weak/No trend (<20) |
Recent upgrades, downgrades, and price target changes (last 90 days)
| Firm | Action | From → To | Date |
|---|---|---|---|
| Guggenheim | REITERATED | Buy → Buy | May 01, 2026 |
| Cantor Fitzgerald | REITERATED | Overweight → Overweight | Apr 30, 2026 |
| Canaccord Genuity | INITIATED | Buy | Apr 21, 2026 |
| RBC Capital | INITIATED | Outperform | Feb 25, 2026 |
| Barclays | INITIATED | Overweight | Feb 20, 2026 |
| Average Target: | $252.93 | High Target: | $328.00 |
| Current Price: | $210.39 | Low Target: | $184.00 |
| Upside to Average: | +20.2% | Number of Analysts: | 29 |
Based on backtest performance (Win Rate: 66.7%, Avg Return: +9.2%) and analyst consensus (Target: $252.93, +20.2% upside), an OVERWEIGHT exposure may be considered. Risk/Reward ratio of 1.35:1 suggests moderate risk-adjusted returns. Current open position shows +3.2% unrealized gain.
AbbVie Inc. operates in the Healthcare sector (Drug Manufacturers - General). Current valuation of 13.0x forward P/E reflects discounted multiples relative to growth prospects. Operating margin of 32.2% shows strong profitability.
Fundamental Outlook: Moderate Growth - Monitoring profitability amid revenue expansion
Overall Score: 5.0/10 - Bullish
Over the last 7 days, the United States market has risen by 1.1%, and over the past 12 months, it is up by an impressive 27%, with earnings expected t...
AZN and ABBV both boast strong drug pipelines and growth outlooks, but differences in valuation, dividends and LOE risks set them apart....
ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence....
ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales....
Realty Income (NYSE:O) is dominating dividend feeds on Reddit and X again, with monthly-payer loyalists pointing to its 113th consecutive quarterly di...
The news sentiment is strongly bullish, indicating positive market perception and favorable coverage. This suggests growing investor confidence and potential upward momentum. Consider this as a supporting factor for bullish positions, but verify with technical and fundamental analysis.
| Metric | Value |
|---|---|
| Market Cap | $371.7B |
| P/E Ratio (Forward) | 13.0 |
| EPS (Forward) | $16.23 |
| Dividend Yield | 3.29% |
| 52-Week Range | $180.25 - $244.81 |
| Beta | 0.30 |
| Avg Volume | 6.8M |
Comprehensive Technical Data for Quantitative Analysis
| Indicator | Value | Indicator | Value |
|---|---|---|---|
| Close Price | $210.39 | Volume | 5.4M |
| EMA 20 | $206.57 | EMA 50 | $209.97 |
| EMA 200 | $213.02 | Current Price | $210.39 |
| RSI (14) | 55.33 | MACD | -0.227 |
| MACD Signal | -1.421 | MACD Histogram | 1.194 |
| Trend Strength (ADX) | 16.92 | Volatility (ATR 14) | $5.44 |
| Bollinger Upper | $213.00 | Bollinger Lower | $195.98 |
| Stochastic %K | 79.28 | Stochastic %D | 73.31 |
| VWAP | $211.44 | Bollinger Middle | $204.49 |
| Confluence Score | 0/7 | Trade Signal | NONE |
Comprehensive Fundamental Data for Financial Analysis
| Valuation Metrics | Performance | ||
|---|---|---|---|
| Market Cap | $371.7B | Revenue | $62.8B |
| Forward P/E | 13.0 | Revenue Growth | +12.4% |
| Trailing P/E | 103.1 | Gross Margin | 72.0% |
| Price/Sales | 5.92 | Operating Margin | 32.2% |
| Price/Book | -55.85 | Profit Margin | 5.8% |
| PEG Ratio | 0.58 | ROE | 0.0% |
| Enterprise Value | $435.3B | Free Cash Flow | $20.8B |
Comprehensive Trading Performance and Position Details
| Entry Date | Entry Price | Past P&L | Entry Stop Loss |
|---|---|---|---|
| 2026-04-29 | $203.89 | +3.19% | $192.49 |
| Entry Date | Exit Date | Entry Price | Exit Price | Return % | Result |
|---|---|---|---|---|---|
| 2023-06-01 | 2023-08-16 | $133.44 | $151.55 | +13.57% | Win |
| 2023-10-19 | 2023-10-23 | $145.52 | $144.73 | -0.54% | Loss |
| 2023-10-27 | 2023-12-07 | $138.93 | $147.97 | +6.51% | Win |
| 2023-12-12 | 2024-04-15 | $153.24 | $161.67 | +5.50% | Win |
| 2024-04-26 | 2024-07-01 | $159.62 | $170.37 | +6.73% | Win |
| 2024-07-25 | 2024-11-13 | $182.17 | $170.35 | -6.49% | Loss |
| 2025-01-22 | 2025-04-10 | $169.20 | $174.20 | +2.96% | Win |
| 2025-09-11 | 2025-09-22 | $220.22 | $222.59 | +1.08% | Win |
| 2025-09-30 | 2025-11-05 | $231.54 | $216.77 | -6.38% | Loss |
| 2025-11-12 | 2026-01-21 | $233.23 | $216.15 | -7.32% | Loss |
Summary: 15 total trades | Strategy: Conservative Stop Loss (Fixed ATR-based)
Disclaimer: This report is for informational and educational purposes only and does not constitute investment advice. Ultra Stock Analysis Pro is not a registered investment advisor; information is impersonal and not tailored to individual circumstances. AI-generated content may contain errors — verify before acting. Past performance is not indicative of future results. Technical analysis based on historical data through 2026-05-15. Fundamental data auto-fetched from Yahoo Finance. Please conduct your own due diligence before making investment decisions.
Report Generated: May 16, 2026 at 12:29 PM
Ultra Stock Analysis Pro - Comprehensive Technical & Fundamental Analysis